Clinical Trials
11
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (9 trials with phase data)• Click on a phase to view related trials
Pilot Study of IC14 (Atibuclimab), an Anti-CD14 Monoclonal Antibody, to Treat STEMI
- Conditions
- STEMIStent ImplantationSTEMI (ST Elevation MI)STEMI - ST Elevation Myocardial Infarction (MI)
- Interventions
- Other: Placebo, 150 mL intravenously, once
- First Posted Date
- 2024-11-07
- Last Posted Date
- 2025-07-25
- Lead Sponsor
- Implicit Bioscience
- Target Recruit Count
- 10
- Registration Number
- NCT06678074
- Locations
- 🇺🇸
University of Virginia, Charlottesville, Virginia, United States
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
IC14 for Treatment of Acute Decompensated Heart Failure
- First Posted Date
- 2024-08-16
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- Implicit Bioscience
- Target Recruit Count
- 10
- Registration Number
- NCT06556810
- Locations
- 🇺🇸
University of Virginia, Charlottesville, Virginia, United States
🇺🇸Virginia Commonwealth University, Richmond, Virginia, United States
Anti-CD14 Treatment With IC14 in Hospitalized ARDS Patients
- Conditions
- Adult Respiratory Distress SyndromeAcute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)Acute Lung InjuryAcute Respiratory Distress Syndrome
- Interventions
- Other: Placebo
- First Posted Date
- 2024-07-22
- Last Posted Date
- 2025-07-25
- Lead Sponsor
- Implicit Bioscience
- Target Recruit Count
- 56
- Registration Number
- NCT06513949
- Locations
- 🇺🇸
Harborview Medical Center, Seattle, Washington, United States
🇺🇸University of Washington, Seattle, Washington, United States
IC14 (Atibuclimab) in Arrhythmogenic Cardiomyopathy
- Conditions
- Arrhythmogenic Right Ventricular DysplasiaArrhythmogenic Left Ventricular CardiomyopathyArrhythmogenic Right Ventricular Cardiomyopathy 1Arrhythmogenic CardiomyopathyACMARVCPKP2
- Interventions
- First Posted Date
- 2024-02-23
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- Implicit Bioscience
- Target Recruit Count
- 5
- Registration Number
- NCT06275893
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸Cleveland Clinic, Cleveland, Ohio, United States
Compassionate Use Open-Label Anti-CD14 Treatment in Patients With SARS-CoV-2 (COVID-19)
- Conditions
- COVIDARDS, HumanArdsSARS-CoV2
- First Posted Date
- 2020-04-15
- Last Posted Date
- 2021-06-21
- Lead Sponsor
- Implicit Bioscience
- Registration Number
- NCT04346277
- Locations
- 🇮🇹
IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milano, Italy
- Prev
- 1
- 2
- 3
- Next